Compare HOLO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLO | LGVN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | China | United States |
| Employees | 74 | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 34.0M |
| IPO Year | N/A | 2021 |
| Metric | HOLO | LGVN |
|---|---|---|
| Price | $1.62 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 550.7K | 399.8K |
| Earning Date | 08-10-2023 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.54 | $0.48 |
| 52 Week High | $11.79 | $1.80 |
| Indicator | HOLO | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 28.50 |
| Support Level | $1.54 | $0.61 |
| Resistance Level | $2.34 | $0.84 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 20.00 | 12.36 |
MicroCloud Hologram Inc provides holographic technology services. Its services include holographic light detection and ranging (LiDAR) solutions, holographic LiDAR point cloud algorithms architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology to service customers that provide holographic driver assistance systems (ADAS). The company also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's operating segments are: Holographic technology service, which generates maximum revenue, and Holographic solutions. Its revenues are mainly generated in the People's Republic of China (PRC).
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.